Lexicon Pharmaceuticals traded at $2.11 this Tuesday December 6th, decreasing $0.05 or 2.31 percent since the previous trading session. Looking back, over the last four weeks, Lexicon Pharmaceuticals lost 0.94 percent. Over the last 12 months, its price fell by 51.27 percent. Looking ahead, we forecast Lexicon Pharmaceuticals to be priced at 2.19 by the end of this quarter and at 1.98 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 103.86 -1.55 -1.47% -21.57%
Acadia Pharmaceuticals 14.90 -0.34 -2.23% -30.11%
Acorda Therapeutics 0.57 -0.01 -2.53% -78.86%
Agios Pharmaceuticals 28.60 -1.20 -4.03% -12.51%
Akebia Therapeutics 0.29 -0.01 -2.46% -89.48%
Alnylam Pharmaceuticals 219.64 -6.56 -2.90% 21.83%
AstraZeneca 11,150.00 -110.00 -0.98% 35.60%
Bluebird Bio 7.83 -0.18 -2.25% -21.31%
BioMarin Pharmaceutical 102.22 -1.31 -1.27% 18.69%
Coherus Biosciences 6.80 0.06 0.89% -62.14%
Clovis Oncology 0.25 -0.04 -13.55% -91.82%
Esperion Therapeutics 7.44 -0.05 -0.67% 33.81%
Halozyme Therapeutics 56.38 0.44 0.79% 74.28%
Intercept Pharmaceuticals 13.99 -0.33 -2.30% -17.46%
Illumina 205.98 -7.88 -3.68% -44.24%
Insmed 18.98 -0.91 -4.58% -32.43%
Ironwood Pharmaceuticals 11.91 -0.09 -0.75% 4.11%
J&J 176.10 -2.68 -1.50% 7.80%
Eli Lilly 368.54 -0.75 -0.20% 50.36%
Lexicon Pharmaceuticals 2.11 -0.05 -2.31% -51.27%
MacroGenics 6.07 -0.31 -4.86% -64.73%
MannKind 4.57 -0.04 -0.87% 3.86%
Merck & Co 108.93 -1.08 -0.98% 50.71%
Moderna Inc 173.54 -2.39 -1.36% -38.54%
Novartis 85.28 -0.52 -0.61% 13.93%
Puma Biotechnology 4.32 0.01 0.23% 40.26%
PTC Therapeutics 39.68 -1.44 -3.50% 4.61%
Ultragenyx Pharmaceutical 39.22 -0.61 -1.53% -53.55%
Regulus Therapeutics 1.52 -0.22 -12.64% 315.07%
Sarepta Therapeutics 120.10 -2.86 -2.33% 40.75%
Thermo Fisher Scientific 550.53 -6.68 -1.20% -12.44%
United Therapeutics 276.60 2.88 1.05% 45.27%
Vanda Pharmaceuticals 10.80 0.19 1.79% -33.54%

Indexes Price Day Year
USND 11015 -225.05 -2.00% -29.78%
US2000 1813 -27.65 -1.50% -19.58%

Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.